Reduction of TGFβ signaling in myeloid cells in the treatment of cancer
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorLi Yang
Life of this patent
Estimating the term…
Abstract
Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGFβ receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.
Claims15
A method of diagnosing cancer and inhibiting cancer metastasis in an individual comprising
- (a) obtaining a sample comprising myeloid cells from the individual;
- (b) determining TGFβ receptor II expression in the myeloid cells, wherein increased TGFβ receptor II expression in the myeloid cells relative to a control indicates a diagnosis of cancer in the individual;
- and
- (c) inhibiting cancer metastasis in the individual, wherein inhibiting cancer metastasis in the individual comprises reducing the TGFβ receptor II expression in myeloid cells in the individual using RNA interference (RNAi), wherein an RNAi agent directly reduces the TGFβ receptor II expression in myeloid cells, thereby inhibiting cancer metastasis in the individual.
A method of diagnosing cancer and inhibiting cancer metastasis in an individual comprising
- (a) obtaining a sample comprising myeloid cells from the individual;
- (b) determining TGFβ receptor II expression in the myeloid cells, wherein increased TGFβ receptor II expression in the myeloid cells relative to a control indicates a diagnosis of cancer in the individual;
- and
- (c) inhibiting cancer metastasis in the individual, wherein inhibiting cancer metastasis in the individual comprises (i) removing myeloid cells from the individual, (ii) reducing the TGFβ receptor II expression in the myeloid cells using RNAi, wherein an RNAi agent directly reduces the TGFβ receptor II expression in myeloid cells, and (iii) administering the myeloid cells to the individual following the reduction in the TGFβ receptor II expression.
A method of diagnosing cancer and inhibiting cancer metastasis in an individual comprising
- (a) obtaining a sample comprising myeloid cells from the individual;
- (b) determining TGFβ receptor II expression in the myeloid cells, wherein increased TGFβ receptor II expression in the myeloid cells relative to a control indicates a diagnosis of cancer in the individual;
- and
- (c) inhibiting cancer metastasis in the individual, wherein inhibiting cancer metastasis in the individual comprises (i) removing bone marrow comprising myeloid cells from the cancer patient, (ii) reducing TGFβ signaling in the myeloid cells of the bone marrow ex viva to yield TGFβ signaling-deficient bone marrow, wherein TGFβ signaling is reduced by reducing the TGFβ receptor II expression in myeloid cells using RNAi, wherein an RNAi agent directly reduces the TGFβ receptor II expression in myeloid cells, and (iii) administering the TGFβ signaling-deficient bone marrow to the individual, so as to inhibit cancer metastasis in the individual.
Dependencies are inferred from the claim text.